Return to homepagePandemic Pact

Corimuno-19: Cohort Multiple randomized controlled trials open-label of immune modulatory drugs and other treatments in COVID-19 patients

  • Funded by Fondation pour la Recherche Médicale
  • Total publications:0 publications

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Known Financial Commitments (USD)

    $138,897

  • Funder

    Fondation pour la Recherche Médicale

  • Principal Investigator

    Pr. Olivier Hermine

  • Research Location

    France

  • Lead Research Institution

    Service d'Hématologie adulte, Hôpital Necker Enfants Malades

  • Research Priority Alignment

    N/A

  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Immunity

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Randomized Controlled Trial

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

The FRM is involved in supporting all the therapeutic trials of the CORIMUNO-19 platform, by funding biological and immunological analyzes in the patients included in the study. These reviews will assess the response to treatment based on the patient profile, in order to aid treatment recommendations and better define future clinical trials.